Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic CMV-specific cytotoxic T lymphocytes (Penn State)
- Development stage
- Discontinued
- Lead developer
- Milton S Hershey Medical Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Investigational adoptive cellular immunotherapy consisting of allogeneic cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTLs) developed by the Milton S. Hershey Medical Center (Penn State). The therapy targets CMV antigens, specifically the pp65 and IE1 proteins, which are expressed in a high percentage of glioblastoma multiforme (GBM) tumors. The therapeutic product is composed of donor-derived CMV-specific CD8+ and CD4+ T cells that are expanded in vitro through stimulation with CMV peptide mixes and conditioning with cytokines IL-2, IL-15, and IL-21. Upon infusion, these CTLs are designed to recognize and eliminate CMV-antigen-positive GBM cells.
- Other names
- CMV-specific cytotoxic T lymphocytesAllogeneic CMV-specific CTLsCMV-CTLcytomegalovirus-specific cytotoxic T lymphocytes-Milton S. Hershey Medical Center-glioblastoma multiforme
02
Targets
pMHC (Peptide-MHC complex family)pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on Allogeneic CMV-specific cytotoxic T lymphocytes (Penn State).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic CMV-specific cytotoxic T lymphocytes (Penn State).